GB2359488A - Restricting reinstatement of drug use - Google Patents

Restricting reinstatement of drug use Download PDF

Info

Publication number
GB2359488A
GB2359488A GB0111220A GB0111220A GB2359488A GB 2359488 A GB2359488 A GB 2359488A GB 0111220 A GB0111220 A GB 0111220A GB 0111220 A GB0111220 A GB 0111220A GB 2359488 A GB2359488 A GB 2359488A
Authority
GB
United Kingdom
Prior art keywords
clonidine
footshock
reinstatement
responses
lever
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0111220A
Other versions
GB0111220D0 (en
Inventor
Dzung Anh Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Britannia Pharmaceuticals Ltd
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Priority to GB0111220A priority Critical patent/GB2359488A/en
Publication of GB0111220D0 publication Critical patent/GB0111220D0/en
Publication of GB2359488A publication Critical patent/GB2359488A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

. a. -2 adrenergic receptor agonists are used as medication for recovering addicts to prevent or reduce relapse by the stress-induced reinstatement of seeking or craving of addictive material. Suitable alpba-2 adrenergic receptor agonists include guanabenz, clonidine, and especially lofexidine. The drugs may be non-opiate such as cocaine, ethanol and nicotine.

Description

2359488
RESTRICTING REINSTATEMENT OF DRUG USE
This invention relates to reducing the probability of reinstatement of drug use.
When a mammal has become addicted to an addictive material it may abstain for example due to non-availability of the addictive material physical or mental treatment or simply wer.
Under some circumstances the abstaining addict will relapse. If a further dose of the addictive material is taken craving may well be induced. In humans if an experimental evidence shows that psychological stress provoked craving for cocaine in cocaine addicts. In rats stress in the form of electric shock induces the relapse of rats addicted to heroin, cocaine, nicotine and alcohol.
Clearly it would be highly desirable if a way of reducing the probability of stressinduced relapse could be found.
It has been unexpectedly found that oc-2 adrenergic receptor agonists reduce the stress-induced reinstatement of addictive material seeking, when the addictive material is a non-opiate selected from cocaine, nicotine and ethanol.
Accordingly we disclose herein a method of reducing the probability of stressinduced reinstatement of addictive material seeking by a mammal comprising administration of an x-2 adrenergic receptor agonist to a rnarnmal abstaining from addictive material use, when the addictive material is a non-opiate selected from cocaine, nicotine and ethanol.

Claims (3)

  1. Hereinafter we claim the use of an ac-2 adrenergic receptor agonist in the
    manufacture of a medicament for reducing the stress-induced reinstatement of cocaine seeking in a person abstaining from nicotine or ethanol use.
    2 Our UK Patent Application GB 0004708.4 claims the use of an cc-2 adrenergic receptor agonist in the manufacture of a medicament for reducing the stressinduced reinstatement of cocaine seeking in a person abstaining from cocaine use.
    Examples of suitable alpha-2 adrenergic receptor agonists include guanabenz, lotexidine and clonidine. Lofexidine is preferred because it tends to have fewer side efFects than guanabenz or clonidine.
    Those skilled in the art will be able to devise suitable means for administering the alpha-2 adrenergic receptor agonist which may be salt form or pro-drug form. The precise method adopted will depend on the material selected examples of possible administration routes may be oral, nasal, transdenng ip and iv.
    Those skilled in the art will be able to determine by routine experiment suitable dosage levels which will depend on the active material and administration route.
    The use of some ac-2 adrenergic receptor agonists in treating the short term side ellects of drug withdrawal is known for example from US 4 800 209.
    In some embodiments of the invention acute withdrawal toms are treated with a medicament other than an alpha 2 adrenergic receptor 3 agonist. By way of non-limiting example the nonapeptide described in US 4 1496 545 could be used.
    It is believed that until now it was not appreciated that these materials were useful in preventing relapse.
    While the applicants do not wish to be bound by this theory it is thought that the intervention between the brain noradrenergic (NE) system and the alpha-2 adrenergic receptor agonists gives rise to the beneficial efFects of the invention.
    Non-limiting examples of the invention and control experiments will now be described by reference to the accompanying figures of which:
    Figure 1. Microdialysis - Prefrontal cortex and amygdala: Mean ( SEM) NE concentrations in 20 min dialysate samples in prefrontal cortex and amygdala. Animals were injected with either clonidine (0, 20, or 40 gg/kg, Lp.), lofexidine (0, 75, or 150 gg/kg, i.p.), or guanabenz (0 or 640 gg/kg, Lp.) at Time 0, and 40 min later were exposed to 10 min of intermittent footshock stress (0.6 mA). Significant Time by Dose interactions were obtained for the prefrontal cortex and amygdala after clonidine (F(16,192)=4.40, p<.O.01 and F(I 6,168)=2.03, p<0.03, respectively), lofexidine ffil 6,168)=5.09 p<.O.01 and F(16,192)--2.09, p<.03, respectively), and guanabenz (F(8,120)=6.22, p<.001). difflerent from high dose only, p<.05.; + diHerent from both other doses, p<.05. 25 Figure 2. Systemic clonidine - reinstatement.. (A) Mean ( SE" number of responses (infusions + timeout responses) on the inactive and previously active levers in the 3 h after an i.p. injection of saline, exposure to 15 min of intermittent footshock stress (0.6 niA), or an i.p. priming injection of cocaine (20 mg/kg). (B) Mean ( SEM) number of responses on the previously active 30 lever in each hour after a saline injection, exposure to footshock stress, or a priming injection of cocaine. Rats were pretreated with vehicle (0) (n--9) or 20 (rrA) or 40 (n---8) gg/kg clonidine, i.p., 40 min before the start of the self- 4 administration session. Lever presses were without consequence during the tests. digerent from vehicle (0) condition, + dilferent from other doses, p<.05.
    Figure 3. Systemic lofexidine - respondingfor sucrose: Mean ( SEM) number of responses on the inactive and active levers 60 min after pretreatment with 0, 80, 120, 160 and 200 ptg/kg lofexidine, i.p. (n---8). Responding on the active lever was reinforced with 0. 18 mI of a 3 0% sucrose solution. different from vehicle (0) condition, p<.05.
    Figure 4. Systemic lofexidine - reinstatement: (A) Mean ( -SEM) number of responses (infusions + timeout responses) on the inactive and previously active levers in the 3 h after an i.p. injection of saline, exposure to 15 min of intermittent footshock stress (0.6 nlA), or an i.p. priming injection of cocaine (20 mg/kg). (B) Mean ( SEM) number of responses (infusions + timeout responses) on the previously active lever in each hour after saline injection, exposure to footshock stress, or a priming injection of cocaine. Rats were pretreated with vehicle (0) (n7-9) or 50 (n--1 1), 100 (n7-11), 150 (n--9), or 200 (n--9) gg/kg lofexidine, i.p., 60 min before the start of the self-administration session. Lever presses were without consequence during the tests. Werent from vehicle (0) condition, + Werent from other doses, p<.05.
    Figure 5. Systemic guanabenz - reinstatement: Mean ( SEM) number of responses (infusions + time out responses) on the previously active lever during 3 h test sessions (no footshock and footshock; saline and cocaine) after pretreatment with 0 or 640 gg/kg guanabenz.
    Figure 6. Approximate location of the injector cannulae tips in the vicinity of the locus coeruleus for rats injected with clonidine and ST91 in Experiment 7. The numbers to the right of each coronal section correspond to the distance from the Interaural fine. LC B locus coeruleus; 7n B facial nerve; 4V B 0 ventricle.
    Figure 7. Systemic injections B clonidine. (A) Mean ( SEM) number of responses (saline infusions+timeout responses) on the active lever in the 3 h after exposure to no-shock, and 5, 15 and 30 min of intermittent footshock (0.5 mA, 0.5 sec ON, a mean OFF period of 40 sec) during tests for reinstatement. Four groups of rats (n---7-8 per group) were pretreated with saline, 10, 20 or 40ptg/kg of clonidine, IP. (B) Mean number of responses on the inactive lever during tests for reinstatement. Significantly different from the clonidine pretreated groups, p<0.05.
    Figure 8. Lateral ventricles B clonidine. (A) Mean number of responses on the active lever in the 3 h after exposure to no shock, and 5 and 15 min of intermittent footshock during tests for reinstatement. Two groups of rats (n---6-7 per group) were pretreated with saline and one dose of clonidine (1 or 3gg) injected into the lateral ventricle. (B) Mean number of responses on the inactive lever during tests for reinstatement. 1 Significantly different from the 1-gg clonidine dose, P<0.05. 2 Significantly different from the 3-gg clonidine dose, p<0.05.
    Figure 9. Locus coeruleus. (A) Clonidine. Mean number of responses on the active and inactive levers in the 3 h after exposure to no shock and 1 5min of intermittent footshock during tests for reinstatement. Rats were pretreated with saline, 1 -gg and 3 -gg of clonidine injected into the LC (n=6). The nostress condition represents the mean of 3 extinction sessions (done in the absence of footshock and intra-LC injections) that were conducted during the tests for reinstatement. (B) ST-91. Mean number of responses on the active and inactive levers in the 3 h after exposure to no shock and 15 min of intermittent footshock during tests for reinstatement. Rats were pretreated with saline, 0.5-gg and 1-gg of ST-91 injected into the LC (n---7). The nostress condition represents the mean of 2 extinction sessions (done in the absence of footshock and intra-LC injections) that were conducted during the tests for reinstatement.
    Figure 10. 4h ventricle B clonidine. (A) Mean number of responses on the active lever in the 3 h after exposure to no shock and 15 nfin of intermittent footshock during tests for reinstatement. Rats (n7-8) were pretreated with saline and clonidine (3gg) injected into the 0 ventricle. (B) Mean number of responses on the inactive lever during tests for reinstatement. Significantly different from clonidine, p<0.05.
    6 Figure 11. Ventral NE bundle lesions. (A) Mean ( SEM) number of responses on the active lever in the first extinction session (left panel) and in the 3 h after exposure to no-shock, and 5 and 15 min of intermittent footshock (0.8 mA, 0.8 sec ON, a mean OFF period of 40 sec) during tests for reinstatement. The data are of 6-01IDA-treated (n--9) and vehicle- treated (n--7) rats. Significantly different from the 6-OHDA group, p<0. 05.
    MATERIALS AND METHODS Experiment 1: Effects of clonidine, lofexidine and guanabenz on footshockinduced NE release Subjects The subjects were male Long-Evans rats (Charles River, Quebec) weighing 300-350 g at the beginning of the experiment. Throughout the experiment, animals were housed in a humidity- and temperature-controlled colony room on a reversed light-dark schedule (lights on 1730-0530 hours) and were given free access to standard laboratory rat chow and water. The experimental procedures followed the CCAC guidelines and were approved by the Animal Care Committee, Concordia University.
    Surgery Before surgery, rats were anaesthetized with sodium pentobarbital (65 mg/kg, i.p.) and were injected with atropine sulfate (0.6 mg/ml; 0.2 ml/rat, SC) and antibiotic (Penlong, Rogar/STB Inc.; 0. 1 mllrat, i.m.). Guide cannulae (20 gauge; Plastics One) were implanted for subsequent insertion of dialysis probes; one was placed in PFC and one in AMG in opposite hemispheres. The animals used to study the effects of guanabenz received a single guide cannula aimed at PFC. The hemisphere into which the respective guide cannulae were implanted was counterbalanced across treatments. The stereotaxic coordinates used (relative to bregma and skull surface) were as follows: AMG, AP -3.0 mm, M1:t43 nim, DV -6.7 nun; P17C, AP +3.2 mm, ML 0.5 mm, DV -1.5 nim (Paxinos and Watson, 1997). Upon insertion, the shaft of the dialysis probe extended 1 nim from the guide cannulae. Implanted guide cannulae 7 were secured to the skull with stainless steel screws and dental cement. Guide cannulae were closed with screw-in obdurators. All animals were returned to the colony room for a recovery period of no less than 1 week prior to testing.
    Microdialysis Nficrodialysis was conducted in four hexagonal testing chambers (42 x 39 x 33.5 em) built from Plexiglas with wooden ceilings and stainless steel rod floors. Dark curtains were drawn around each chamber and lighting was provided on a reversed cycle by overhead light bulbs (15 W). The dialysis probe consisted of a 1. 8 nun (AMG) or 3.5 10 nun (PFC) length of semipermeable dialysis membrane (Spectra/Por; 240 gm o.d., 13000 M.W. cutoff), closed at one end and attached at the other to a 19 mm length of 26 gauge stainless-steel tubing. A 40- to 50-cm length of PE-20 tubing connected the other end of the stainless steel shaft to an infusion swivel stationed above the testing chamber that was in turn connected via PE-20 tubing to a variable-speed infusion pump.
    A small diameter, flised-silica tube extended internally through the probe, with one end resting 0.5 mm from the tip of the probe and the other end exiting the PE tubing 35 em below the infusion swivel. The external length of PE-20 tubing was protected from damage by steel spring casings. The probes were designed so that the entire length of semi- permeable membrane extended below the guide cannula tip.
    Separate squads of animals were used to examine the effects of each of the drugs tested. Within each squad, each animal was randomly assigned to the treatment condition. Animals that received vehicle injections were run in each squad, but were combined into a single group for statistical analysis. Final group sizes (PFC/AMG) were as follows: vehicle (n = 15/17), clonidine 20 gg/kg (n = 7/6), clonidine 40 gg/kg (n = 9/5), lofexidine 75 [tg/kg (rr--616), lofexidine 150 gg/kg (n = 5/6), guanabenz 640gg/kg (n = 4, PFC). With the exception of the animals receiving guanabenz, all sub ects were dialyzed twice, once in the PFC and once in the AMG with an interval j of 3-4 weeks between tests.
    The probes were inserted the day before the beginning of microdialysis testing. To prevent occlusion, artificial CSF (145 mM Na+, 2.7 mM Kt, 1. 22 mM Ca2+, 1.0 mM 8 Mg2+,150 mM Cl-, 0.2 mM ascorbate, 2 mM Na211P04, pH 7.4 0. 1) was perfused overnight at a rate of 0.06 gl/min. Dialysate sampling and activity monitoring began the next morning. The dialysate flow rate was increased to 0.6 gl/ min, and baseline dialysate samples (12 pLI/ sample) were collected every 20 min. Samples were collected until a stable baseline, defined as a minimum of 3 consecutive samples in which dialysate NE levels varied by:110%, was achieved. Following the establishment of stable baseline NE levels, all animals received an i.p. injection (1 ml/kg) of the appropriate drug or vehicle which was given 40 min before a 10 min period of footshock. Shocks were delivered on a variable time schedule at a mean interval of 40 s (10-70 s range); each shock (0.6 mA) was 0.5 s in duration. Samples were collected for a flifther 120 min (6 samples). Samples were immediately analyzed using one of two similar high-performance: liquid chromatography systems with electrochemical detection (HPLC-EC). The samples (10 gl) were loaded onto reverse-phase columns (15 x 0.46 cm; HAISIL Cl 8, 5 pLnr, Sci. Products & Equipment, Concord, Ontario) through manual injection ports (Reodyne 7125; 20 gl loop); reduction and oxidation currents for NE, dihydroxyphenylacetic acid (DOPAC), 5-hydoxyindoleacetic acid (5-IHAA) and hornovanillic acid (RVA) were measured with dual-chamel ESA coulornetric detectors (Coulochern 5100, with a model 5021 conditioning cell and a model 5011 analytical cell, Sci. Products & Equipment). The currents for NE were measured independent of those for DOPAC and HVA using separate channels of the Coulochern detectors. The mobile phases (sodium acetate 36 mM, SOS 3.1 mM, EDTA 100 pLM, 5% acetonitrile, adjusted to pH 3.7 using glacial acetic acid) were circulated through each closed system at a flow rate of 1.4 ml/min by Waters 5 10 HPLC pumps. The peaks obtained for NE, DOPAC and HVA were integrated and quantified by EZChrorn Chromatography Data System (Sci. Products & Equipment). Dialysate samples from individual rats always were analyzed with the same HPLC-EC system, and the assignment of animals to each system was counterbalanced across all treatment groups. Food was removed from the chambers before sampling, but a water drinking tube was available. At the completion of testing, confirmation of correct probe placement was determined by examination of 30 gm sections cut through the sites of probe placement stained with Cresyl violet.
    9 Experiment 2: Ellects of clonidine on footshock- and cocaine-induced reinstatement Subjects The subjects were 25 male Long-Evans rats (Charles River, Quebec) weighing 350425 g at the start of the experiment. The animals were maintained as described in Experiment 1.
    Surgery Animals were prepared for surgery as described in Experiment 1. An intravenous catheter (Dow Coming) was implanted in the right jugular vein. A 3-cm length of silastic tubing was inserted into the vein (inner diameter 0.30 nun, outer diameter 0.64 mm) and was connected with heat shrink tubing to a 9-cm length of silastic tubing (inner diameter 0.51 mni, outer diameter 0.94 mm) that was passed subcutaneously to the top of the skulL The catheter was secured to the vein with silk sutures and exited into a connector (a modified 22 gauge cannula; Plastics One, Roartoke, VA) that was mounted to the skull with jeweler's screws and dental cement; a plastic cap was placed over the opening of the cannula. Animals were allowed 1-2 weeks to recover from surgery.
    Apparatus The self-administration chambers used in the experiments were equipped with a retractable lever (Med Associates, St Albans, VT) and a non- retractable "dununy" lever. Both levers were located 9 cm above the floor. An infusion pump (Razel Scientific Instruments, Stamford, CT) was activated by responses on the retractable, or "active," lever. Responses on the dummy lever were recorded but did not result in activation of the pump. Drug solution was delivered over a 1 0-s period in a volume of 65 gl. Throughout the infusion period, a white stimulus light just above the active lever was illuminated and additional responses during this time were recorded, but did not result in reactivation of the pump. Each selfadministration chamber was fitted to deliver constant-current, internfittent, inescapable, electric footshock through a scrambler to the grid floor (Grason-Stadler Generator #E 1 064GS). The footshock was delivered for 15 min according to a variable time schedule at a mean interval of 40 s (10-70 s range). Each shock (0.6 rnA) was 0.5 s in duration. This intensity of footshocks has been found using our apparatus to be the minimal required to induce reliable reinstatement.
    Drugs Cocaine HO was obtained from BDH Chemicals (Toronto, Canada) and was dissolved in physiological saline. Clonidine HCl was purchased from Sigma (St Louis, MO) and was dissolved in physiological saline and injected Lp. (0, 20, and 40 gg/kg).
    Procedure Phase 1: Training. Rats were trained to self-administer cocaine FIC1 (0.5 mg/kg/infusion, im.) on a fixed-ratio-1 schedule of reinforcement during one daily 3-h self-administration session. Each day, half of the animals were brought to the operant chambers for their self-administration session in the morning, approximately 3 hours after fights off, and half of the animal were brought to the chambers in the afternoon, approximately 7 hours after lights oiT The group of animals assigned to the morning and afternoon sessions alternated daily so that by the end of training all animals had received an equal number of self-administration sessions at both times. It was important that all a had similar experience self-administering early and late in the day since during Phase 2 all animals received extinction sessions in the morning followed by a test session that typically occurred in the afternoon. At the beg of each session, a red house fight was illuminated for 10 s before introduction of the retractable lever into the cage. The fight just above the active lever was fit for the initial 30 s following presentation of the lever. The house fight remained illuminated throughout the session. As indicated previously, responses on the active lever resulted in activation of the infusion pump and illumination of the light above the lever for the 10 s of drug delivery. Additional lever presses during the drug-delivery period were recorded but did not result in reactivation of the pump. Training conditions were in place for 10 to 12 days. At the end of training, animals were left 11 undisturbed in the colony room for 7 to 13 days. Subsequently, extinction and testing took place. In this experiment and in Experiment 3B, groups of an were assigned to diffierent doses of the test drugs. All animals in each group were then subjected to three test conditions; saline, cocaine and footshock.
    Phase 2: Extinction and testing. During extinction and testing, which occurred over 4 consecutive days, a were housed 24 h per day in the selfadministration chambers. Food and water were freely available to animals, except during daily extinction and test sessions. Animals were brought to the chambers in the evening preceding the first day of extinction and testing. Since two separate groups of rats were run each day during the training phase, one group of animals was tested in the first 4 days of Phase 2 and the other group of animals was tested in the next 4 days. During extinction and testing, all of the conditions that were present during training were maintained except that lever presses did not result in cocaine infusions.
    In this and all subsequent reinstatement experiments, animals were given several daily 1 -h extinction sessions separated by intervening periods in which the lever was withdrawn. On day 1, animals were given 4 extinction sessions; on days 2-4, animal were given 2 to 3 extinction sessions, sufficient to establish a baseline level of responding of 15 or fewer responses in 1 h, followed by a 180 min test session. duration of the intervening periods was kept constant for each experiment and corresponded to the delay required for drug absorption between pretreatment injections and the start of the test. In the present experiment, the duration of intervening periods was 40 min.
    The At test, separate groups of an were pretreated with either 0, 20, or 40 gg/kg, i.p., clonidine before each of three tests for reinstatement (saline, cocaine, and footshock), given on consecutive days and in a counterbalanced order. Clonidine was injected 40 min before the lever was inserted. For the saline and cocaine priming tests, animals were given a non-contingent, i.p., injection of saline or cocaine (20 mg/kg) 5 before lever insertion. For the footshock tests, animals were exposed to the 15-min brief intermittent footshock stress immediately before insertion of the lever.
    12 Experiment 3A: Effects of lofexidine on high rates of responding for sucrose Because the pharmacological profile for lofexidine has not been as well characterized as that for clonidine, an experiment was conducted to establish whether, and at what doses, lofexidine induces performance deficits. The doses in the tests for reinstatement were chosen on the basis of results obtained in this experiment.
    Subjects The subjects were 8 male Long-Evans rats (Charles River, Quebec) weighing 400-550 g at the beginning of the experiment. Rats were previously used in an experiment aimed at studying footshock-induced reinstatement of sucrose seeking. Animals were maintained under similar conditions to those described in Experiment 1.
    Apparatus Each self-administration chamber was equipped with two stationary levers, symmetrically centered on one side panel, 5 cm above the floor. Responses on one lever, the "active" lever, activated a pump (Razel Sci. Stamford, CT). Responses on the other lever, the "dummy" lever, were recorded but were without consequence. Activation of the pump resulted in a 20 s delivery of 0. 18 mi sucrose solution to a liquid drop receptacle located between the two levers. Throughout the sucrose delivery period, a white stimulus light just above the active lever was illuminated and additional responses during this time were recorded but did not result in reactivation of the pump.
    Drugs Lofexidine HCI was supplied by Britannia Pharmaceuticals Ltd., M The drug was dissolved in physiological saline and injected i.p. (0, 80, 120, 160 or 200 ptg/kg).
    Procedure Animals that had previously learned to self-administer sucrose were subsequently given 5 sessions over 5 consecutive days in which they self-administered a 30% sucrose solution on an FR-1 schedule. In subsequent daily sessions, animals were injected with either vehicle (0 pig/kg) or lofexidine (80, 120, 160 or 200 ptg/kg, i.p.) 13 min before the start of the self-administration session. All animals received all doses of lofexidine in a counterbalanced order; the highest dose of lofexidine was tested twice. Each session in which animals were treated with lofexidine was followed by a saline pretreatment session to minimize the possibility of carry-over 5 effects of the drug.
    Experiment 3B: Effects of lofexidine on footshock- and cocaine-induced reinstatement Subjects The subjects were 49 male Long-Evans rats (34 from Charles River, Quebec; 15 from Harlan Sprague Dawley, USA) weighing 350-400 g at the beginning of the experiment. The animals were maintained as described in Experiment 1. There were no obvious dilferences in responding between a from the two suppliers in any 15 phase of the experiment.
    Procedure Phase 1: Training. A were U-dined to self-administer cocaine under the conditions described in Experiment 2.
    Phase 2: Extinction and testing. In this experiment the intervening periods, as described above, were 60 min in duration. At test, separate groups of animals were pretreated with either 0, 50, 100, 150, or 200 gg/kg, i.p., lofexidine before each of three tests for reinstatement (saline, cocaine, and footshock stress), given on consecutive days and in a counterbalanced order (see Experiment 2). Lofexidine was injected 60 min before the insertion of the lever. Test sessions were 3-h in duration. The doses of lofexidine were chosen on the basis of the results obtained in Experiment 3A.
    Experiment 4: Effects of guanabenz on footshock- and cocaine-induced reinstatement 14 Subjects The subjects were 18 male Long-Evans rats (Charles River, Quebec) weighing 350400 g at the beginning of the experiment. The animals were maintained as described in Experiment 1.
    Drug Guanabenz was purchased from Sigma (St Louis, MO) and was dissolved in physiological saline and injected i.p. (0, and 640 gg/kg).
    Procedure Phase 1: Training. Animals were trained to self-administer cocaine under the conditions described in Experiment 2.
    Phase 2: Extinction and testing. In this experiment the intervening periods, as described above, were 60 min in duration. At test, animals were pretreated with 0 or 640 gg/kg guanabertz, i.p., before each of two tests for reinstatement (no footshock, footshock or saline, cocaine), given on consecutive days (see Experiment 2). Guanabenz was injected 60 nfin before the insertion of the lever. Test sessions were 3-h in duration. The dose of guanabenz was chosen on the basis of its substitutability for 40 gg/kg clonidine in a drug discrimination procedure.
    Statistical analyses Microdialysis data were analyzed using a mixed-factor ANOVA for concentration of extracellular NE in 20 min dialysate samples; the between-subjects factor was dose of clonidine (0, 20, 40 gg/kg), lofexidine (0, 75, or 150 gg/kg), or guanabenz (0 or 640 ig/kg) and the repeated measure was time. Significant tirne by dose interactions were subjected to one-way ANOVAs for the factor of dose at specific time points. When appropriate, post hoc tests (Fisher's LSD, p<.05) were conducted to compare vehicle (0 gg/kg) to drug conditions.
    The two dependent measures in the tests for reinstatement were number of responses on the active lever (infusions + time out responses) and number of responses on the inactive lever in 3 h. All behavioral data are presented as means SEM. Because of considerable variability in the number of responses made in the different tests for reinstatement, the non-parametric statistics for related (Friedman and Wilcoxon) and unrelated (Kruskal-Wallis and Mann- Whiney) samples were used where appropriate.
    For the sucrose study (Experiment 3A) the dependent measures were the number of responses on the active (reinforced + timeout responses) and inactive levers and the number of reinforcements obtained. Repeated measures ANOVAs were conducted with Dose as the within-subject factor. When appropriate, post hoc tests (Fisher's 10 LSD, p<.05) were conducted to compare vehicle (0 gg/kg) to drug conditions.
    RF,SULTS Experiment 1: Effects of clonidine, lolexidine and guanabenz on footshockinduced NE release Figure 1 shows basal and footshock-induced levels of NE in PK (top row) andlor AMG (bottom row) after injection at Time 0 with clonidine (left panel), lofexidine (center panel), or guanabenz (right panel). Mixed-factor ANOVAs revealed significant Time by Dose interactions in both brain regions and for each of the three drugs. The statistics for each of these interactions are indicated in the figure legend.
    One-way ANOVAs conducted at specific time points were, when statistically significant, followed by post-hoc comparisons (Fisher's LSD). Significant differences are indicated in Figure Experiment 2: Effects of clonidine on footshock- and cocaine-induced reinstatement Training and Extinction The mean ( SEM) number of infusions of 0.5 mg/kg cocaine made in the 3-h session on the last two days of training was 32.24 ( 2.77) and 25.76 ( 2.96), respectively.
    The mean ( SEM) number of responses (infusions + time out responses) made during the first three 1 -h extinction sessions on day 1 of Phase 2, was 28.92 ( 2.81), 13.16 16 ( 2.03), and 9.68 ( 2.04). There was no difrerence in the rate of extinction between animals tested in the first 4 days of Phase 2 and those tested 4 days later.
    Tesisfor reinstatement The number of responses made on the active and inactive levers during each 3-h test for reinstatement followingpretreatment with clonidine is shown in Figure 2A.
    Figure 2B shows the number of responses on the active lever during each hour of testing. It can be seen that pretreatment with 20 or 40 pg/kg clonidine blocked fbotshock-induced relapse to cocaine seeking, but had no effiect on relapse induced by a priming injection of cocaine. Kruskal-Waflis tests conducted at each hour of testing revealed a significant effect of dose of clonidine in the footshock cond ition in Hour 1, when most of the responding occurred (X2 (2)=6.0, p<.05, footshock); both doses of clonidine were effective (ps<.05). There were no significant ef[ects of clonidine in either the saline or cocaine conditions in Hour 1; no effects were seen in any of the test conditions in Hours 2 or 3. Figure 2A shows that responding on the inactive lever was low under all pretreatment and test conditions. This was the case in all subsequent reinstatement experiments, where there were no significant efFects of the number of responses on the inactive lever.
    Experiment 3A: Effects of lofexidine on responding for sucrose Figure 3 shows the total number of responses (reinforced + tirne out responses) on the active and inactive levers, and the number of sucrose reinforcements made, following injections of vehicle (0 pg/kg) or lofexidine. There was no effect of lofexidine on the number of responses on the active lever, F(4,28)=1.79, ns. There were, however, Dose elTects on the number of reinforcements and number of responses on the inactive lever, F(4,28)=2.80, p<0.05 and F(4,28)=2.85, p<0.05, respectively; this reflects the fact that when compared with the vehicle (0 g/kg) condition, animals obtained fewer sucrose reinforcements and made fewer responses on the inactive lever following pretreatment with the highest dose of lolexidine (200 gg/kg).
    17 Experiment 3B: Eftects of lofexidine on footshock- and cocaine-induced reinstatement Training and Extinction The mean ( SE" number of cocaine infusions made in the 3-h session on the List two days of training was 30.07 ( 2.37) and 30.91 ( 2.06), respectively. On day 1 of extinction, the mean ( SE" number of responses made in the first three 1 - h extinction sessions (infusions + time out responses) was 31.32 ( 3.22), 16.84 ( 3.29), and 16.23 ( 2.35). There was no difference in the rate of extinction between animals tested in the first 4 days and those tested in the subsequent 4 days of Phase 2.
    Tesisfor reinstatement Figure 4A shows the number of responses made on the active and inactive levers during each 3-h test for reinstatement following pretreatment with vehicle (0 gg/kg) or lofexidine. Figure 413 shows the number of responses on the active lever during each hour of testing. It can be seen that both footshock stress and priming injections of cocaine induced reinstatement of cocaine seeking behavior. Only the efred of footshock stress was attenuated by lofexidine. This is confirmed by the Kruskal Wallis tests conducted for the 3-h tests for reinstatement where the only significant effect was found in the footshock condition 0 (4)=10.50, p<.05). Subsequent Mann-Whitney comparisons revealed a significant diflerence between the 0 and 150 gg/kg and 0 and 200 [tg/kg lofexidine doses (ps<.05); furthermore, the response to footshock after 150 and 200 pLg/kg doses did not difFer from the responses in the salirte condition. Separate analyses conducted at each hour of testing revealed a significant effiect, again, only in Hour 1 of testing (X2 (4)= 17.3 1, p<. 0 1, footshock), when all doses of lofexidine blocked the footshock efFect (ps<.05).
    Experiment 4: Effects of guanabenz on footshock- and cocaine-induced reinstatement Training 18 The mean ( SEM) number of infusions of cocaine made in the 3-h session on the last two days of training was 36.63 ( 3.56) and 40.12 ( 3.65), respectively.
    Testsfor reinstatement Figure 5 shows the number of responses made on the active lever in tests for reinstatement after pretreatment with either 0 or 640 gg/kg guanabertz. It can be seen that guanabenz attenuated the effect of footshock stress. A Friedman analysis on the footshock and no footshock tests revealed a significant effect of test condition, X2(3)=8.36, p<.05, and subsequent comparisons using the Wilcoxon test showed that the footshock (0 gg/kg) condition difFered from the others (ps<.05). Inspection of Figure 5 also reveals what appears to be a reduction in responding in the cocaine test following pretreatment with guanabertz. However, a comparison of the scores on the cocaine test using the Mann- VAfitney revealed no significant difference between the two groups (0 and 64Ogg/kg; z=0.73, p=.46).
    Initially, the egect of pretreatment with clonidine, injected systemically or into the ventricles, on footshock stress-induced reinstatement was tested in heroin-trained rats. To determine whether the effects observed were due to its action on the LC neurons, clonidine or its charged analogue, ST-91, were also injected into this area. It was found that although clonidine was highly effective in blocking stress- induced reinstatement when injected systemically or into the ventricles, intra-LC injections of clonidine or ST-91 were not. The role of the lateral tegmental NE nuclei in stressinduced reinstatement was also assesed. The neurotoxin 6-Hydroxydopamine (6OHDA) was injected into the ventral NE bundle that carries ascending neurons from the lateral tegmental NE nuclei. The lesions were done 1-2 days after training for heroin self-administration and the effect of this manipulation on extinction behavior and stress-induced reinstatement was determined.
    Material and methods Subjects A total of 120 male Long-Evans rats (Charles River, Quebec; or Wilmington, M& 350-400 g) served as the subjects. The animals were housed in the colony room for at 19 least one week before surgery and were allowed to recover for 5-7 days after surgery. They were then transferred to the operant chambers where they were housed, with free access to water and food, for the duration of the experiment on a reverse lightdark cycle (lights on 10:00 PM - 10:00 A. ". The experimental procedures followed the Society for Neuroscience and the CCAC guidelines, and were approved by the Animal Care Committee of the Addiction Research Foundation (Exp. 1-4) and NIDA/IRP (Exp. 5).
    Surgery The an were surgically implanted with intravenous (IV) silastic catheters (Dow Coming, Nfidland, NII) in the right jugular vein under anaesthesia. The anaesthetic agents used were either xylazine (10 mg/kg, IP) + ketamine HQ (100 mg/kg, IP) or sodium pentobarbital (65 mg/kg, IP). Atropine sulfate (0.4 mg/kg, SC), penicillin G (150,000 1U, 0. 1 mI, IM) and buprenorphine (0.0 1 mg/kg, SC) were given at the time of surgery (penicillin G and atropine were not given to the rats used in Exp. 5). The catheter was secured to the vein with a silk suture and passed subcutaneously to the top of the skull where it exited into a connector (a modified 22 gauge cannula., Plastic One, Roanoke, VA) mounted to the skull with jewellers screws and dental cement. The catheters were flushed every 24-48 h with sterile saline (0.05 ml). The intracranial cannulae (24 gauge, Plastic One) were implanted during the IV surgery. The flat skull coordinates (Paxinos & Watson, 1996) for the right lateral ventricle were -0.9 nun from bregma, +1.4 mm lateral to the midline, and -2.0 mm from the skull surface. The coordinates for the 0 ventricle were B 1.0 mm from the interaural line, 0 mm from the midline, and +4.2 mm from the interaural line. The coordinates for the LC (stereotaxic arms set at 100 from the vertical plane, bilateral cannulae) were -0.9 or B1.0 mm from the interaural fine, +0.9 mm lateral to the midline, and +4.6 mm from the interaural line. The LC injection sites for rats included in the present report are presented in Figure 6. The coordinates (Pellegrino et al., 1979) for the ventral NE bundle were -6.6 mm from bregma, +2.8 mm lateral to the midline, and -7.7 mm from the skull surface. The stereotaxic arms were set at 50 from the vertical plane and the incisor bar was set at +5 mm.
    Apparatus The operant chambers had two levers located 9 cm, above the floor, but only one lever (an active, retractable lever; Med Associates) activated the infusion pump (Razel Sci., Stamford, CT). Presses on the other lever (an inactive, stationary lever) were recorded, but did not activate the infusion pump. A given drug dose was d at a volume of 0. 13 mI and a titneout period of 20 sec was given after each drug infusion; during this time period a cue light located above the active lever was turned on.
    Throughout the experiment, each session began with the introduction of the retractable lever into the cage and the illumination of the white cue light above the lever for 30 sec. A red house light was turned on for the entire sessioa The grid floors of the chambers were connected to electric shock generators (Med Associates, Georgia, VT).
    Drugs Diacetylmorphine HO (heroin, a gift from NIDA, USA), Pargyline HQ clonidine HO (Sigma, St Louis, MO), and ST-91 (2-[2,6-diethylphenylamino]-2- iniidazole, a gift from Boehringer Ingelheirn, Ridgefield, CT) were dissolved in sterile physiological saline. 6-OHDA hydrobromide (Sigma) was dissolved in ascorbic acid dissolved in physiological saline (0. 15 mg/nil). Clonidine was given IP (1040 gg/kg), into the lateral ventricle (0.2 and 0.6 gg/5 gL; 1 and 3 gg/rat), into the 4th ventricle (1.5 gg/2 gL; 3 gg/rat) and intra-LC (2 and 4 gg/0.5 gL/site; 1- 2 gg/site).
    ST-91 was given intra-LC (2 jig/0.25 gL/site or 2 gg/0.5 gL/site, 0.5 or 1 gg/site).
    For intracranial injections, clonidine and ST-91 were infused by Hamilton syringes over 45-60 sec and the injector was removed after additional 45-60 sec and was immediately replaced by a cannula blocker. The injectors were lowered 1 mm below the tip of the cannulae for lateral ventricle injections and 2 mm below the tip of the cannulae for 4th ventricle and LC injections.
    6-01[DA lesion The 6-OHDA lesion procedure was based on previous reports (Sahajian et al. , 1983; Aston-Jones et al., 1999). The drug or the vehicle were infused via the pre-implanted cannulae. The lesions were done 1-2 days after the end of the training phase and the 21 rats were allowed 5-7 days to recover after the lesion procedure before the start of the extinction phase. The rats were injected with pargyline (50 mg/kg, IP) 30 min before the drug/vehicle injections. The rats were anaesthetized with the ketaminc+xylaxine mixture (see above). 6-OHDA (3 gg/pLL) or the vehicle were d bilaterally by Hamilton syringes connected to a Harvard Apparatus infusion pump over 4 min at two dorsal-ventral placements (-8.7 and -9.7). The infusion volume per placement was 1 gL and the injector remained in place for an additional 4 min after the infusion.
    The effectiveness of the lesion manipulation was tested by an UPLC assay for NE in 4 brain regions, the frontal cortex, the hippocarnpus, the hypothalarnus and the bed nucleus of the stria terniinalis (BNST). (The former two regions are solely innervated by the LC neurons (Moore & Bloom, 1979) and should not be allected by the lesion procedure. The latter two regions are innervated by the lateral tegmental NE neurons and to a lesser degree by the LC neurons (Moore & Bloom, 1979; Fritschy & Grzanna, 199 1) and, therefore, the lesion should significantly decrease NE content in these regions.) At the end of the experiment, the rats were decapitated, the brain was quickly removed and fitted, ventral side up, in an ice-cold rodent brain matrix. The first coronal cut was made about 0.6 mm anterior to bregma (anterior part of the optic chiasm). Two additional cuts were made posterior to thefirst. The brain was removed from the matrix and placed on an ice-cold petri dish. The frontal poles of the cortex were cut from the most anterior brain section. The BNST was removed from the section posterior to the first slice (about + 0.6 to B 0.6 from bregma). First, a midline section containing the septal nucleus and diagonal band of Broca was removed and discarded. The BNST was extracted by cutting, laterally, a 1 nim2 section of grey matter below the lateral ventricle and dorsal to the anterior commissure. The hypothalamus and hippocampus were taken from the fflird section (about B 0.6 to B 2.6 mm from bregma). The tissue sections were kept in small vials in a -700 freezer until assayed.
    Tissue Assays The frozen tissue was thawed and centrifuged at 4,000 rpm for 15 min. The supernatant was analyzed for amine content using two high-performance liquid chromatography systems with electrochernical. detection BPLC-EC. Pellets were used 22 for protein analysis. The samples were loaded onto reverse-phase columns (15 x 0.46 cm; HAI SIL Cl 8, 5 gm, Sci. Products & Equipment, Concord, Ontario) through manual injection ports (Reodyne 7125; 20 gl loop). Reduction currents for NE were measured with dual-channel ESA coulometric detectors (Coulochem 5 100, with a model 5021 conditioning cell and a model 5011 analytical cell, Sci. Products & Equipment). The mobile phase (sodium acetate 36 mM, SOS 3.1 MM, EDTA 100 piM, 5% acetonitrile, adjusted to pH 3.7 using glacial acetic acid) were circulated through each closed system at a flow rate of 1.4 ml/min by Waters 515 F1PLC pumps.
    The concentration of NE was estimated from peak height by comparison with injections of known amounts of pure standards (Sigma) using EZChrom Chromatography Data System (Sci. Products & Equipment). The response of the chromatographic system is linear between amine concentrations of 100 pg and 1,000 pg/ 10 gl-injection (r's > 0.98). Intra-assay variability was <5%. Values are expressed as pg/g protein.
    Procedure Experiments were run in three phases: self-administration training, extinction and tests for reinstatement. Forty subjects of the 120 subjects were excluded from the final analyses due to poor health, catheter blockade, unreliable self- administration behavior (i.e., unstable low drug-intake or no increase in rate of responding in the first day of extinction) or misplaced cannulae. Many animals were excluded from the experiments in which injections were to be made into the LC or the 0 ventricle because of the difficulty of obtaining accurate placements. The numbers of animals mentioned below refer only to those included in the analyses.
    Training. Rats were trained to self-administer heroin (0. 1 mg/kg/hifusion, IV) for 910 days under a fixed ratio- 1 schedule of reinforcement (FR- 1, each lever press is reinforced) with a 20-sec timeout period after each injection. Each day was divided into three 3-h sessions separated by 3 h. The first session of each day started at the beginning of the dark period. Each session began with the introduction of the retractable lever into the cage and the illumination of the cue light above the lever for 23 sec. A red house fight was turned on for the entire session and was turned off at the end of each session. Under these conditions, stable drug-taking behavior (25% or less of variation from the mean) is obtained after about 4-5 days in the majority of the rats.
    Extinction. During the extinction phase, saline was substituted for heroin. The rest of the conditions remained the same as in training. In Exp. 5-9 the extinction phase started 1 day after the last training day. In Exp. 10 (ventral NE bundle lesions) the extinction phase started 5-7 days after the 6-OHDA procedure that was conducted 1-2 days after the end of the training phase. Initially, the rats were given three, 3-h selfadministration sessions each day for 5 days. Subsequently, the 3-h extinction sessions were given once per day at the start of the dark cycle for 2-6 additional days until the rats reached the extinction criterion of less than 20 responses (saline ion+timeout responses) on the active lever. At this point, the testing phase started. Aft daily test sessions were done at the start of the dark cycle.
    Tests for reinstatement Experiment 5: Systemic injections - clonidine. For this experiment, the within subject factor was the footshock duration (0, 5, 15 and 30 min) and the between subjects factor was the dose of clonidine (0, 10, 20 or 40 [ig/kg, IP; n7-7-8 per dose). After reaching the extinction criterion, the rats were pretreated with the vehicle or clonidine and were exposed, 30 min later to dillerent durations of footshock (administered in an ascending order) in 4 consecutive daily sessions. Intermittent footshock (0.5 mA, 0.5 sec on, with a mean off period of 40 sec) was given immediately before the start of the test sessions. Tests for reinstatement were conducted under extinction conditions.
    During the no footshock condition (0-min), the rats were left undisturbed for 15 min before the start of the test session.
    Experiment 6: Lateral ventricles - clonidine. Two groups were tested for the efflect of acute pretreatment with clonidine on reinstatement induced by exposure to footshock. The between subject factor was the dose of clonidine (1 or 3 gg, ICV, n7-6-7 per dose) and the within subject factors were the pretreatment condition (vehicle and clonidine) 24 and the footshock duration (0, 5 and 15 min). That is, after reaching the extinction criterion, each rat was exposed, in a counterbalanced order, to the vehicle alone, vehicle+5 min of footshock, vehicle+ 15 min of footshock, clonidine alone, clonidine+5 min of footshock and clonidine+15 min of footshock. The tests were administered daily for 6 consecutive days and clonidine was given 10-20 min before exposure to footshock. During the no footshock condition ffl-min), the rats were left undisturbed for 15 min before the start of the test session. Cannulae placements were verified by giving each rat an infusion of 100 ng/4 gL of angiotensin and observing subsequent drinking behavior. Placements were considered to be accurate if a rat 10 started drinking within 1 min of the infusion and sustained drinking over 2-3 min.
    Experiment 7: Locus coeruleus B clonidine and ST-91. One group of animals (n=6) was tested for reinstatement induced by exposure to footshock (15 min) after injections of saline or clonidine (1-2 gg/side) into the LC. These doses of clonidine were based on the results of Experiment 6. In pilot studies we found that neither clonidine (03-2 gg/side) nor saline injections given alone had effiects on baseline lever pressing behavior during tests for reinstatement (data not shown). This result allowed us to limit possible damage to this small structure from repeated injection by testing each subject only twice, once after exposure to vehicle+ footshock and once after exposure to 1 gg clonidine+fbotshock. These tests were given in a counterbalanced order separated by 48 h; a baseline extinction session was given on the intervening day. Subsequently, because the 1 gg of clonidine only partially attenuated footshock-induced reinstatement, rats were given another baseline session day and then 24 h later were injected with 2 gg/site of clonidine prior to exposure to footshock. Clonidine was injected 5-15 min before exposure to footshock.
    A second group (rr--7) was tested for reinstatement induced by exposure to footshock (15 min) after injection of saline or ST-91 (0.5 and 1 gg/side) into the LC. This group was added because of the inconclusive results obtained with intra-LC injections of clonidine. Specifically, we used high doses of clonidine at a relatively high infusion volume (0.5 gL) for a small brain structure such as the LC. Therefore, any attenuation of footshock-induced reinstatement by clonidine in the LC under these conditions might have been due to difflusion of this lipophilic compound into the 0 ventricle and consequently to actions of clonidine at other brain sites. Therefore, ST9 1, a charged analogue of clonidine, which is less likely to dilluse away from the injection site, was given at a low volume of 0.25 ptL. The doses of ST-91 used were based on observations that this compound inhibits the cell firing of the LC neurons at somewhat lower doses than clonidine when injected centrally. Initially, after reaching the extinction criterion, each subject was tested, in a counterbalanced order, after exposure to vehicle+footshock and after exposure to ST-9 l +footshock (0.5 gg/side, 0.25 gL) in 2 daily tests. Because of the lack of egect of 0.5 gg/side ST-91, a third test was conducted after pretreatment with a higher volume and a higher dose of ST91 (1 gg/side, 0.5 gL). ST-91 was injected 5-15 min before exposure to footshock. At the end of the experiment, the rats were overdosed, injected with 0.25-0.5 gL of Evans Blue (2.5%; Signia), and perfimd transcardially with 0.9% saline followed by 10% formalin. The brains were removed and sliced in 40-pm frozen sections for verification of cannulae placements.
    Experiment 8: 4 ventricle - clonidine. In this experiment we thought to determine whether the mild ef Fect of clonidine seen following injections into the region of the LC might have been due to the difflision of this compound from the site of injection into the 0 ventricle. Animals (n-78) were tested for reinstatement induced by exposure to footshock (15 min) after injections of saline or clonidine (3 gg/rat) into the 0 ventricle. After reaching the extinction criterion, each rat was exposed, in a counterbalanced order, to the vehicle alone, vehicle+footshock, clonidine alone and clonidine+footshock. The tests were administered daily for 4 consecutive days and clonidine was given 10-20 min before exposure to footshock. During the no-shock condition (0-min), the rats were left undisturbed for 15 min before the start of the test session. At the end of the experiment the rats were overdosed, injected with 2 gL of Evans Blue (2.5%), and perfused transcardially with 0. 9% saline followed by 10% formalin. The brains were removed and sliced in 40 gm frozen sections for verification of cannulae placements.
    Experiment 9: Ventral NE bundle lesions. For this experiment, the within subject 26 factor was the footshock duration (0, 5 and 15 min) and the between subjects factor was the lesion manipulation (6-OHDA versus vehicle, ri-77- 9 per group). After reaching the extinction criterion, the rats were exposed to difrerent durations of footshock (administered in an ascending order) in 3 consecutive daily sessions. Intermittent footshock (0.8 mA, 0. 8 sec on, with a mean offperiod of 40 sec) was given immediately before the start of the test sessions. Tests for reinstatement were conducted under extinction conditions. During the no footshock condition ffl-min), the rats were left undisturbed for 15 min before the start of the test session.
    Statistical analyses Data from the tests for reinstatement were analysed separately for total non-reinforced responses on the active lever (saline ffifusion+Atimeout@ responses) and responses on the inactive lever. Due to large individual variations and skewed distributions, a square root transformation was used before the data were subjected to the statistical analyses. In cases where the pharmacological manipulations or footshock exposure altered responses on the inactive lever (a measure of nonspecific activity), statistical analyses were conducted on change scores (ie., responses on the active lever minus responses on the inactive lever). These analyses were done on raw scores because in a few cases the change-score values were negative.
    Experiment 5: Systemic injections B clonidine. Four groups of rats were tested with one dose of clonidine (0, 10, 20 or 40 gg/kg) and exposed to 4 durations of footshock (0, 5, 15 and 30 min). The between subject factor in the statistical analyses was Clonidine Dose and the within subject factor was Stress Duration (0, 5, 15 and 30 rnin).
    Experiment 6: Lateral ventricles - clonidine. Two groups were tested with the vehicle and one dose of clonidine (1 or 3 pig) and exposed to 3 durations of footshock (0, 5 and 15 min). The between subject factor in the statistical analyses was Clonidine Dose, and the within subject factors were Pretreatment Condition (saline and clonidine) and Stress Duration.
    27 is Experiment 7.. Locus coeruleus. Clonidine. Each subject was given 3 tests for reinstatement after exposure to footshock and pretreatment with saline, 1 gg and 2 gg of clonidine. These tests were done 48 h apart and the subjects were given baseline extinction sessions without injections or footshock exposure in the intervening days. The repeated measures ANOVA analyses were done on the data from the 3 test days with footshock using Clonidine Dose as the repeated measures factor. ST-91. Each subject was given 3 tests for reinstatement after exposure to footshock and pretreatment with saline, 0.5 gg and 1 gg of ST-91 in 3 consecutive days. The repeated measures ANOVA analyses included the data from these test days using ST91 Dose as the repeated measures factor.
    Experiment 8: 4' ventricle B clonidine. Rats were tested with the vehicle and one dose of clonidine (3 gg) and exposed to 2 durations of footshock (0 and 15 min) in 4 daily tests. The within subject factors in the statistical analyses were Pretreatment Condition (saline and clonidine) and Stress Duration.
    Experiment 9: Ventral NE bundle lesions. Two groups of rats were exposed to 3 durations of footshock (0, 5 and 15 min). The between subject factor in the statistical analyses was Lesion and the within subject factor was Stress Duration.
    In all experiments, in cases of significant main efFects, subsequent dillerences between the various experimental conditions were examined by post hoc contrasts (SAS, General Linear Model). Significant differences are reported for p values of less than 0.05.
    Results Training and extinction. No significant diferences were observed between the different experiments in the self-administration behavior during the training and the extinction phases. For A animals (n7--80), the mean+_SEM number of infusions and total responses (heroin infusions+timeout responses) on the active lever during the first session of the last day of training were 11.5+_+0.6 and 29.5 3.0, respectively. The mean number of responses on the inactive lever was 1.2 0.2. All rats increased 28 their rate of responding on the active lever on the first session of extinction. The number of Musions and total responses (saline infusions+ timeout responses) on the active lever and the number of responses on the inactive lever were 31.1 1.5, 120.7 10.7 and 2.9 0.4, respectively.
    Tests for reinstatement Experiment 5: Systemic injections B clonidine. Systemic injections of clonidine blocked footshock-induced reinstatement. The between subject factor in the statistical analyses was Clonidine Dose (0, 10, 20 and 40 ptg/kg) and the within subject factor was Stress Duration (0, 5, 15 and 30 min). The analysis of total responses on the active lever (saline inflisions+timeout responding) revealed significant ellects of Clonidine Dose (F[3,26]=10.4, p<0.01), Stress Duration (F[3, 78]=1. 1.7, p<0.01) and a significant Clonidine Dose by Stress Duration interaction (F[9,78]=8.9, p<0.01). Clonidine also decreased responding on the inactive lever, whereas footshock increased responding on this lever. The statistical analyses revealed significant elfects of Clonidine Dose (F[3,261=7.0, p<0.01), Stress Duration (F[3,781=3.8, p<0.01) and a significant Clonidine Dose by Stress Duration interaction (F[9,781=2.5, p<0.05). Because of the efficts on the inactive lever, an additional analysis was done using change scores (i.e., responses on the active lever minus responses on the inactive lever). The results of this change- score analysis were similar to those obtained for the analysis of the active lever. Significant eflects were observed for Clonidine Dose (F[3, 261=7.0, p<0.01), Stress Duration (F[3,781=7.3, p<0.01) and for the Clonidine Dose by Stress Duration interaction (F[9,78]=4.9, p<0.01). These elfects indicate that after taking into account the e:Wects of footshock and clonidine on inactive lever responses, increased footshock duration enhanced responding on the active lever in the saline condition, while clonidine blocked footshock-induced reinstatement regardless of the shock duration. Results of the post hoc tests are shown in Figure 7. Experiment 6: Lateral ventricles - clonidine. Injections of both doses of
    clonidine into the lateral ventricle decreased footshock-induced reinstatement. The statistical analyses for total responses on the active lever revealed significant eflects of 29 Pretreatment Condition (F[1,1 11=32.5, p<0.01), Stress Duration (F[2, 22]=15.9, p<O. 0 1) and a significant Pretreatment Condition by Stress Duration interaction (F[1,111=10.8,p<0.01). Clonidine also decreased responding on the inactive lever, as revealed by the effect of Pretreatment Condition (F[1,111=10.7, p<0.01). Therefore, an additional analysis was conducted on change scores (i.e., responses on the active lever minus responses on the inactive lever). The results of this change- score analysis were similar to those obtained for the analysis of the active lever. Significant effiects were observed for Pretreatment Condition (F[1,1 11=10.6, p<0.01), Stress Duration (F[2,221=6.2, p<0.01) and Pretreatment Condition by Stress Duration (F[2,221=4.4, p<0.05). These ellects indicate that after taking into account the effect of clonidine on inactive lever responses, footshock increased responding on the active lever in the saline condition, while clonidine attenuated footshock-induced reinstatement. Results of the post hoc tests are shown in Figure 8.
    Experiment 7Locus coeruleus. Clonidine. Intra-LC injections of clonidine appeared to attenuate footshock-induced reinstatement of heroin seeking, but the effect was only partial and not dose-dependent (Figure 9). The statistical analysis carried out on the total number of responses made following exposure to footshock after pretreatment with vehicle, 1 gg and 2 gg of clonidine revealed a marginally 20 significant effect of Clonidine Dose (F[2,101=3.8, p=0.058). Intra-LC clonidine did not alter rate of responding on the inactive lever following exposure to footshock (F [2,1 01=2.4, ns).
    ST-91. Intra-LC injections of ST-91 had no consistent effect on footshockinduced reinstatement of heroin seeking (Figure 9). The statistical analysis carried out on the total number of responses made following exposure to footshock after pretreatment with vehicle, 0.5 gg and 1 gg of ST-91 showed that effect of ST-91 Dose was not significant (F[2,121=0.9, ns). Intra-LC ST-91 did not alter rate of responding on the inactive lever following exposure to footshock (F[2,12]=0.5, ns).
    Experiment 8: 4 1h ventricle B clonidine. Clonidine injected into the 4 h ventricle significantly attenuated footshock-induced reinstatement (Figure 10). In this experiment animals were tested with both the vehicle and one dose of clonidine (3 gg) and were exposed to two durations, of footshock (0 and 15 n-fin) over 4 daily tests.
    The analyses for total responses on the active lever revealed significant effects of Pretreatment Condition (F[1,71=8.9, p<0.05), Stress Duration (F[1,71=16.1, p<0.01) and a significant Pretreatment Condition by Stress Duration interaction (F[ 1,7]= 10.8, p<0.01). There was also an effect of Stress Duration on responses on the inactive lever (F[1,71=7.9, p<0.05). Therefore, an additional analysis was conducted on change scores (i.e., responses on the active lever minus responses on the inactive lever). The results of this change-score analysis were similar to those obtained for the analysis of the active lever, indicating that the eflect of footshock on reinstatement is not due to a non-specific increase in activity. Significant effiects were observed for Pretreatment Condition (F[1,7]=13.3, p<0.01), Stress Duration (F[1,71=5.9, p<0.05) and for the Pretreatment Condition by Stress Duration interaction (F[2, 22]=7.5, p<0.05). Results of the post hoe tests are shown in Figure 10.
    Experiment 9: Ventral NE bundle lesions. The lesion manipulation resulted in a significant decrease in NE levels in the hypothalamus (6-OHDA [n--91: 38. 6 5.6 pg/g of protein; vehicle [n--71: 72.1 13.8, t(14)=2.4, p<0.05) and the BNST (6- OHDA:
    27.7 3.6; vehicle: 64.8 1 0. 0, t(l 4)=3.8, p<O. 05), but not in the frontal cortex (6 OHDA: 8.8 0.9; vehicle: 9.9 1.1, t(14)=0.8, ns) or the hippocampus (6- OHDA:
    5.9_+0.4; vehicle: 7.1 0.6, t(14)=1.7, ns). It can be seen in Figure 11 that the lesions significantly attenuated stress-induced reinstatement.. The analysis of total responses on the active lever (saline infusions+timeout responding) revealed significant effects of Lesion (between factor, F[ 1, 14]=9. 1, p<0.0 1), Stress Duration (within factor, F[2,28]=53. 1, p<0.01) and a significant Lesion by Stress Duration interaction (F[2,281=10.6,p<0.01). The lesion manipulation had no efFect on responding on the inactive lever (F[ 1, 14]=0. 6, ns). Results of the post hoe tests are shown in Figure 11.
    This figure also shows rate of responding during the first extinction session. Rate of responding during this session and during subsequent extinction sessions (data not shown) of the 6-011DA-treated rats did not diffierent from that of the vehicle-treated rats.
    Systemic injections of clonidine and lofexidine attenuate the footshockinduced reinstatement of cocaine seeking, but have no effect on reinstatement induced by priming injections of cocaine. Second, the alpha2 adrenergic, receptor agonist, guanabertz, which unlike clonidine and lofexidine has a low affinity for 11 receptors also attenuates footshock-induced reinstatement. These efflects were obtained by drugs that at similar doses and under similar stress parameters to those used in the tests for reinstatement suppressed the footshock-induced increase in NE release in AMG andlor PFC in naive animals. These findings suggest that reduction of brain NE activity may be an effective way to prevent stress-induced relapse to cocaine seeking.
    The effects of clonidine and lofexidine observed in this study could have been mediated through their actions at I I rather than alpha-2 receptors. The nM affinity of clonidine for the alpha-2 receptor is 28 2.6 and for the I, receptor is 0.9M.43; the affinity of lofexidine for these receptors is almost identical. Alpha-2 and I, receptors have been shown, however, to be difflerentially involved in biochemical and behavioural efFects of alpha-2 adrenergic receptor agonists. For example, in drug discrimination studies, alpha-2 receptors appear to be responsible for a clonidineinduced cue, for which both lofexidine and guanabenz (a compound with n1A affinity for alpha-2 receptor of 7.2_+_0.6 and for the 11 receptor of >1,000,000) substitute dose- dependently. On the other hand, 11 receptors of the medulla are thought to mediate the antihypertensive actions of these drugs. Although not definitive in view of the fact that guanabenz was not tested independently for rate-reducing effects, it appears unlikely that the attenuation of the footshock-induced reinstatement of cocaine seeking was I,-receptor mediated; guanabenz, a drug with a low affiffity for the 11 receptor, attenuated footshock-induced reinstatement of cocaine-seeking at a dose that has been shown to substitute for 40 gglkg clonidine in a drug discrimination task.
    Three issues might be seen to complicate the interpretation of the present findings. First, clonidine, lofexidine and guanabenz might affect motor performance; second, these drugs might act at peripheral rather than central receptors; and finally, it is possible that the analgesic actions of these drugs mediate their elfect on footshockinduced reinstatement. With respect to the first, it is unlikely that the egects were due 32 to a performance deficit. In the saline and cocaine priming conditions, neither clonidine, lofexidine nor guanabenz reduced responding on the active lever. Furthermore, the doses of clonidine and lofexidine used in the tests for reinstatement were chosen because they had little or no effect on high rates of responding for sucrose. After the highest dose of clonidine tested (40 pg/kg) in sucrose- trained animals, animals responded nearly 100 times in 20 min; likewise, in Experiment 3A, animals injected with the highest dose of lolexidine (200 gg/kg) obtained close to 40 reinforcements in 30 min and demonstrated no significant reduction in response rate.
    The possibility that the effects observed in the present study were due to the actions of the alpha-2 agonists at peripheral rather than central receptors also seems unlikely. First, we found in a study with herointrained rats that i.c.v. injections of clonidine were as effective as systemic injections in blocking the footshock-induced reinstatement. Additionally, systemic injections of 40 pLg/kg ST-91 (the charged analogue of clonidine which does not effiectively cross the blood brain barrier) have been given to cocaine-trained animals. The ST-9 1 -treated animals show a comparable footshock-induced reinstatement of responding (90.75 26.37 in 3 hr) to vehicletreated animals (1 15.63:t 24.49 in 3 hr). It would appear, therefore, that the efflects of systemic injections of clonidine on footshock-induced reinstatement of both heroin and cocaine seeking are mediated centrally.
    Finally, it seems unlikely that footshock-induced reinstatement of drug seeking is mediated by analgesic effects of these drugs at the doses used. Observations made during the footshock sessions revealed that both vehicle- and drug-pretreated animals reacted similarly to the footshocks throughout the shock period. These observations are consistent with the finding that clonidine, within a similar dose range to the one used in the present study, does not alter threshold sensitivity to footshock.
    The data suggests that activation of central NE systems by footshock contribute to its effect on reinstatement of heroin seeking. The ellects of systemic or ventricular injections were not evident after intra-LC injections of clonidine or its charged analogue, ST-91, suggesting that the LC-NE, cell group does not mediate the 33 reinstatement of heroin seeking by footshock stress. 6-OHDA lesions of the ventral NE bundle significantly decreased footshock-induced reinstatement, suggesting that the NE neurons that originate in the lateral tegmental nuclei in the pons and medulla, as well as the adrenergic neurons that originate from these area, contribute to relapse induced by stressors. Thus, a possible site of action for the eflect of clonidine on footshock stress-induced reinstatement is the cell body region of the lateral tegmental neurons. It has been reported that these groups of neurons are inhibited by clonidine. In addition, anatomical studies have shown that the lateral tegmental NE cell groups project to brain areas involved in the stress response such as the hypothalamus, the 10 central nucleus of the amygdala, the BNST and the septum.
    The observation that clonidine blocks footshock-induced reinstatement when injected into the 0 ventricle might suggest that the main action of clonidine is in the region of the cell bodies. Lipophilic compounds can, however, diffluse against the flow of the cerebrospinal fluid in the ventricular system, making it is possible for 0 ventricle injections of clonidine to reach forebrain areas. Another possibility is that clonidine had its efrect via postsynaptic alpha-2 receptors located on non-NE neurons. A number of studies have shown that alpha-2 adrenergic receptor agonists have behavioral and neurochernical effects when injected locally into terminal regions of the NE system. However, because clonidine at doses higher than those used here are needed to activate the less sensitive postsynaptic alpha-2 adrenergic receptors, it is likely that the predominant effect of clonidine in the present study was on the more sensitive presynaptic alpha-2 adrenergic receptors.
    One confounding interpretation of the present data is that clonidine blocks footshockinduced reinstatement by interfering with motor performance. This appears unlikely, in view of the lack of eflect of clonidine on responses on the active lever in the absence of footshock (Fig. 7, 8 and 10). Furthermore, several studies, using the drug discrimination methods, have shown that although clonidine at doses of 1040 gg/kg does decrease high rates of lever pressing, rats can lever press 25-50 times/min at these doses. Tests were conducted for possible sedative ellects of these doses of clonidine in seven rats given daily 20-min sessions in which they lever pressed for a 34 10% sucrose solution. Although a modest reduction in response rate after clonidine pretreatment at the 40-gg/kg dose was found, the responses/20 min after saline, 10, 20 and 40 gg/kg of clonidine were 127 18, 111 14, 121 24, 93 1 5, respectively (unpublished data). It might also be suggested that the analgesic actions of clonidine mediate its effiect on footshock-induced reinstatement. This seems unlikely, however, in that the analgesic effects of clonidine are manifested at doses 5-10 higher than those used here and clonidine, at a dose range similar to the one used in the present report, did not alter threshold sensitivity to footshock.
    Low doses of clonidine also indirectly decrease 5-HT cell firing and release. However, a low dose of the 5-HT1a autoreceptor agonist, 8-011DPAT (25 gg/kg), known to decrease 5-HT cell firing and release had no efFect on footshock-induced reinstatement. In 11 rats trained and tested under identical conditions to the ones described here, the mean number of responses made in the first 3 hr after exposure to 15 min of intermittent footshock was 43.8 6.6 in rats pretreated with the vehicle and 36.4 3.3 in rats pretreated with 8-011-DPAT. Even though only one dose of the drug was used, these data suggest that the blockade of stress-induced reinstatement by clonidine is not due to an indirect efrect on the 5-HT system. In addition, although the efrects of clonidine seen here are independent of its efficts on the 5-HT system other systems may be involved. Clonidine binds at high affiffity to the I, imidazoline receptor.
    An important issue to be addressed is the relation between the present data and the previous finding that CRF receptor antagonists attenuate the efflect of footshock on reinstatement of heroin seeking. Based on studies showing CRF/LC-NE interactions in stress responses, it has been hypothesised that CRF receptor antagonists alter stress-induced reinstatement by decreasing the responsiveness of the LC-NE system to footshock. The lack of an effect of intra-LC clonidine or ST-91 on footshockinduced reinstatement was, therefore, somewhat surprising. The present data, however, are consistent with findings showing that diTerent stressors activate the LCNE system via diffierent neuronal pathways.
    Many studies have shown that alpha-2 adrenergic receptor agonists attenuate responses to stressors by their action on the LC neurons. Therefore, an unexpected finding is that the efrect of clonidine on footshock-induced reinstatement is independent of its action on the LC-NE neurons. It should be pointed out, however, that this observation is not unique to the phenomenon of stress-induced reinstatement. It has been shown that the reduction in locomotor activity induced by clonidine was similar in sham-treated rats and in rats exposed to neurochernical lesions of the LC. In addition, high doses of clonidine (0.1-0.2 mg/kg) are equally efIective in preventing opioid withdrawal symptoms in sham rats and in rats with dorsal NE bundle lesions that selectively lesion the LC neurons.
    In conclusion, the present data demonstrate that clonidine blocks footshock-induced reinstatement of heroin seeking by actions that are independent of the LC-NE system. Based on the data from animals with the 6-OHDA lesions of the ventral NE bundle, we speculate that this action of clonidine is mediated by the NE neurons of the lateral tegmentum. The lesion manipulation, however, was not as effective in attenuating stress-induced reinstatement as were systemic or ventricular injections of clonidine. These difFerences might be due to incomplete lesions or recovery of flinction after the 6-011DA injections. The present data also cannot rule out the possibility that clonidine acts on postsynaptic alpha-2 adrenoceptors located on non-NE neurons in terminal regions. Finally, these results indicating that NE neurons of the lateral tegmental nucle but not of the LC, are involved in the aversive effects of opioid withdrawal, suggest that this system is involved in addiction processes. In addition, the findings presented here may provide a rationale for the use of the alpha-2 adrenergic receptor agonists, lofexidine and clonidine, in treatment programs for the prevention of relapse to drugs of abuse. The current use of these drugs in the shortterm treatment of acute opioid withdrawal, though useful, does not prevent relapse to drug use following its termination. According to the invention a more prolonged period of treatment may be efficacious.
    First, the invention provides a rationale for the use of alpha-2 adrenergic receptor agonists in treatment programs for the prevention of relapse to drug use. Currently, 36 these drugs are being used with some success in the short-term treatment of opioid withdrawal. The present findings suggest that they may be effiective in the treatment of cocaine users if given for a more prolonged period. Second, the present experiments demonstrate a similar eflicacy of clonidine and lofexidine in preventing footshock-induced reinstatement of cocaine seeking. This finding is of potential clinical significance in that lofexidine has been reported in humans to be associated with fewer adverse side efFects than clonidine, in particular fewer hypotensive eflects.
    37 CLAIMS 1. The use of an alpha-2 adrenergic receptor agonist, a physiologically acceptable salt thereof or a pro-drug thereo in the manufacture of a medicament for reducing the stress-related reinstatement of addictive material seeking in a person abstaining from addictive material use characterised in that the addictive material is a non-opiate selected from cocaine, nicotine and ethanol, and the non-opiate is ethanol or nicotine.
  2. 2. A use as claimed in claim 1 wherein the alpha-2 adrenergic receptor agonist is guanabenz, lofe)ddine or clonidine.
  3. 3. The use of lofexidine or a physiologically acceptable salt or pro-drug thereof in.the manufacture of a medicament for reducing the stressrelated reinstatement of 15 ethanol or nicotine-seeking in a person abstaining from ethanol or nicotine use.
GB0111220A 2000-02-28 2000-02-28 Restricting reinstatement of drug use Withdrawn GB2359488A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0111220A GB2359488A (en) 2000-02-28 2000-02-28 Restricting reinstatement of drug use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0004708.4A GB0004708D0 (en) 2000-02-28 2000-02-28 Restricting reinstatement of drug use
GB0111220A GB2359488A (en) 2000-02-28 2000-02-28 Restricting reinstatement of drug use

Publications (2)

Publication Number Publication Date
GB0111220D0 GB0111220D0 (en) 2001-06-27
GB2359488A true GB2359488A (en) 2001-08-29

Family

ID=9886566

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0004708.4A Ceased GB0004708D0 (en) 2000-02-28 2000-02-28 Restricting reinstatement of drug use
GB0111220A Withdrawn GB2359488A (en) 2000-02-28 2000-02-28 Restricting reinstatement of drug use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0004708.4A Ceased GB0004708D0 (en) 2000-02-28 2000-02-28 Restricting reinstatement of drug use

Country Status (8)

Country Link
US (1) US20040077636A1 (en)
EP (1) EP1267849B1 (en)
AT (1) ATE289194T1 (en)
AU (1) AU2001237550A1 (en)
DE (1) DE60108947T2 (en)
ES (1) ES2236183T3 (en)
GB (2) GB0004708D0 (en)
WO (1) WO2001064201A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009691A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
WO2009120735A1 (en) * 2008-03-27 2009-10-01 Us Worldmeds Llc Composition and method for transmucosal delivery of lofexidine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
US7245902B2 (en) 2002-01-16 2007-07-17 2 Ergo Limited Secure messaging via a mobile communications network
EP3473251B1 (en) 2002-12-20 2023-12-13 NicoNovum AB A nicotine-cellulose combination
JP5694645B2 (en) 2006-03-16 2015-04-01 ニコノヴァム エービーNiconovum Ab Improved snuff composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800209A (en) * 1981-12-14 1989-01-24 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US4382946A (en) * 1981-12-14 1983-05-10 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US4783456A (en) * 1984-03-02 1988-11-08 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4788189A (en) * 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
PT99629A (en) * 1991-11-28 1993-05-31 Antonio Feria Reis Valle Method for detoxification of opiates
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
WO1996014071A1 (en) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combination of chemical compounds used as a medicament intended to suppress the dependence of individuals to opioids
US5789411A (en) * 1995-09-11 1998-08-04 Lance L. Gooberman P. C. Improvements to rapid opioid detoxification

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur. J. Neurosci., 12, 292-302, (2000) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009691A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
WO2007009691A3 (en) * 2005-07-15 2007-03-08 Esteve Labor Dr Combination of substituted pyrazolines and anti -addictive agent
WO2009120735A1 (en) * 2008-03-27 2009-10-01 Us Worldmeds Llc Composition and method for transmucosal delivery of lofexidine

Also Published As

Publication number Publication date
GB0004708D0 (en) 2000-04-19
DE60108947D1 (en) 2005-03-24
WO2001064201A2 (en) 2001-09-07
GB0111220D0 (en) 2001-06-27
US20040077636A1 (en) 2004-04-22
ATE289194T1 (en) 2005-03-15
ES2236183T3 (en) 2005-07-16
AU2001237550A1 (en) 2001-09-12
EP1267849A2 (en) 2003-01-02
EP1267849B1 (en) 2005-02-16
DE60108947T2 (en) 2005-10-27
WO2001064201A3 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
Shaham et al. Relapse to heroin-seeking in rats under opioid maintenance: the effects of stress, heroin priming, and withdrawal
Levy et al. Analgesia produced by microinjection of baclofen and morphine at brain stem sites
Shaham et al. Clonidine blocks stress‐induced reinstatement of heroin seeking in rats: An effect independent of locus coeruleus noradrenergic neurons
Pontieri et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs
Hull et al. Dopaminergic control of male sex behavior in rats: effects of an intracerebrally-infused agonist
Bancroft et al. Ventral hippocampal α4β2 nicotinic receptors and chronic nicotine effects on memory
Brazell et al. Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: a dose-response and antagonist study
Walker et al. Microinjections of an opiate receptor antagonist into the bed nucleus of the stria terminalis suppress heroin self-administration in dependent rats
Bubar et al. Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens
Boyce et al. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats
Chan et al. D1-like dopamine receptor dysfunction in the lateral habenula nucleus increased anxiety-like behavior in rat
Hagan et al. Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics
Harris et al. β-adrenergic antagonism alters the behavioral and neurochemical responses to cocaine
Edwards et al. Tissue uptake of ketamine and norketamine enantiomers in the rat Indirect evidence for extrahepatic metabolic inversion
GB2359488A (en) Restricting reinstatement of drug use
Alps Drugs acting on calcium channels: potential treatment for ischaemic stroke.
Maisonneuve et al. Biphasic dose-related effects of morphine on dopamine release
Woods et al. Exogenous tyrosine potentiates the methylphenidate-induced increase in extracellular dopamine in the nucleus accumbens: a microdialysis study
Paterson et al. Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats
London et al. Effects of chronic nicotine on cerebral glucose utilization in the rat
Steinmiller et al. Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine
Yang et al. Dopamine D2 receptors in the posterior region of the nucleus tractus solitarius mediate the central pressor action of quinpirole (LY171555)
Baldwin et al. Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses
Di Pirro et al. Amniotic-fluid ingestion enhances the central analgesic effect of morphine
Pan et al. Differential effects of chloral hydrate and pentobarbital sodium on a cocaine level and its catecholamine response in the medial prefrontal cortex: a comparison with conscious rats

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)